Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Laura Helbling

Laura Helbling is Director of Research at Prevision Policy and a Senior Writer at The RPM Report (now Pink Sheet). Laura has a degree in magazine journalism from the University of Missouri School of Journalism.

Latest From Laura Helbling

Ex-Commissioners See Mostly Positives In Public View Of US FDA After COVID

Three of the US FDA’s former leaders believe the agency is coming through COVID with its reputation intact. They still support making the agency independent of the broader Health & Human Services Department, but the urgency may be gone.

FDA Politics

US FDA Exploring Options To Improve Study Of Drugs In Elderly

New incentives will most likely not be the immediate focus, but working group to explore ideas on enhancing understanding of drug effects in elderly populations will likely be formed by US FDA.

Research & Development Drug Approval Standards

Not So Fast: Trump Team Paints US FDA Review Times As Too Slow

New ‘statement of policy’ directs US FDA to publish charts of its approval timeliness – using an outdated 180-day benchmark to make its approval speed look worse.

Drug Review FDA

US FDA ‘Bruised’ But Not Broken: Former Commissioners See Agency Intact Amid Transition

Three former commissioners believe FDA has come through the Trump administration relatively unscathed when compared to the reputational damage suffered by other government agencies. Will the Biden team agree?

FDA Leadership

‘Bruised’ But Not Broken: Ex-Commissioners See FDA Intact Amid Transition

Three former commissioners believe FDA has come through the Trump Administration relatively unscathed when compared to the reputational damage suffered by other government agencies. Will the Biden team agree?

FDA Elections

Rx Vial Size: FDA Stresses Safety Issues Amid Push To Find Savings For Payors

There may be significant savings from eliminating wasteful packaging for high cost specialty drugs. The US FDA, however, is urging policy makers not to overlook the importance of patient safety in packaging issues.

Drug Safety Government Payers
See All
UsernamePublicRestriction

Register